pharma · Growth Hormone Deficiency, Pediatric
Ascendis Pharma
Ascendis Pharma Endocrinology Division A/S
Ascendis Pharma clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Palo Alto, USA
- Founded
- 2010
- Employees
- 5
- Programs
- 2
- Drugs
- 7
- Patents
- 6
Ascendis Pharma projects
2 ClinicalTrials.gov programs sponsored by Ascendis Pharma.
Ascendis Pharma has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ASND0047
Ascendis Pharma Endocrinology Division A/S
Turner Syndrome (TS), idiopathic short stature (ISS), short stature homeobox containing gene deficiency (SHOX-D), small for gestational age (SGA)
1 trial -
Once weekly subcutaneous injection of TransCon hGH
Ascendis Pharma Endocrinology Division A/S
Growth Hormone Deficiency, Pediatric
1 trial
Frequently asked questions
How many clinical projects does Ascendis Pharma have?
2 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.